Search

Displaying results 2801 - 2810 of 7018 in total
  1. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary … It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome.

  2. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.

    Categories: Vitamins (Fat Soluble)
  3. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    Ferrous bisglycinate is a chelate that is used as a source of dietary iron. … Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional [A27250].

  4. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.

  5. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. … Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  6. Drug

    Procyclidine

    go.drugbank.com/drugs/DB00387
    ApprovedInvestigational

    A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.

  7. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  8. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

  9. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

  10. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.